MYL Share Price

Open 36.79 Change Price %
High 37.02 1 Day 0.00 0.00
Low 36.35 1 Week -2.22 -5.70
Close 36.73 1 Month -1.09 -2.88
Volume 5031791 1 Year -12.98 -26.11
52 Week High 54.23
52 Week Low 33.60
MYL Important Levels
Resistance 2 37.35
Resistance 1 37.10
Pivot 36.70
Support 1 36.36
Support 2 36.11
NASDAQ USA Most Active Stocks
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
DRYS 1.87 0.00%
ACAS 17.99 0.39%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
LINE 0.18 12.50%
ATEA 1.90 11.76%
ATEA 1.90 11.76%
KITD 0.30 11.11%
SGYPU 10.75 10.26%
LPHI 0.24 9.09%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
THTI 0.15 -40.00%
More..

Mylan Inc. (NASDAQ: MYL)

MYL Technical Analysis 4
As on 13th Jan 2017 MYL Share Price closed @ 36.73 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 42.37 & Sell for SHORT-TERM with Stoploss of 37.24 we also expect STOCK to react on Following IMPORTANT LEVELS.
MYL Target for January
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
MYL Other Details
Segment EQ
Market Capital 10603874304.00
Sector Consumer Durables Major Pharmaceuticals
Industry
Offical website
MYL Address
MYL
N/A
MYL Latest News
Interactive Technical Analysis Chart Mylan Inc. ( MYL NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Mylan Inc.
MYL Business Profile
Mylan Inc. (Mylan) is a fully integrated global pharmaceutical company that develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. Mylan has two segments:Generics and Specialty. Its generic pharmaceutical business is conducted primarily in the United States and Canada (collectively, North America); Europe, the Middle East, and Africa (collectively, EMEA); and India, Australia, Japan and New Zealand (collectively, Asia Pacific). Its API business is conducted through Mylan Laboratories Limited (Mylan India), which is included within the Asia Pacific region in its Generics Segment. The Company's pharmaceutical business is conducted by Mylan Specialty L.P. (Mylan Specialty). Mylan provides products to customers in approximately 140 countries and territories. In December 2013, In December 2013, the Company announced that it has completed the acquisition of the Agila injectables businesses from Strides Arcolab Ltd.